MedlineMDLN +2.79%16 EBITDA Margin % is 9.66% as of Mar. 2026, which is 5% below its 10-year median of 10.12. GuruFocus rates MDLN with a GF Score™ of 16/100. The stock has 3 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Medline ranks better than 56.37% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Medline's EBITDA for the
three
months ended in Mar. 2026 was $710 Mil. Medline's Revenue for the
three
months ended in Mar. 2026 was $7,352 Mil. Therefore, Medline's EBITDA margin for the quarter that ended in Mar. 2026 was 9.66%.
Medline (NAS:MDLN) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Medline EBITDA Margin % Related Terms
Medline EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Medline's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Medline's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medline EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medline's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Medline's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medline (MDLN) has a EBITDA Margin % of 9.66% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medline and its competitors. This is near median its historical median of 10.12. Over the past decade, Medline's EBITDA Margin % has ranged from 8.46 to 12.10. According to the industry distribution chart, Medline ranks #356 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 43.6%.
Is Medline's EBITDA Margin % too high?
Medline's current EBITDA Margin % of 9.66% is near median its 10-year median of 10.12. Over the past 10 years, this metric has ranged from a low of 8.46 to a high of 12.10. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Medline's value of 9.66% is 29.2% above this industry median. Based on the distribution chart, Medline ranks #356 out of 816 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Medline has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Medline's EBITDA Margin % compare to RMD and WST?
According to the Medical Devices & Instruments industry distribution chart, Medline ranks #356 out of 816 companies for EBITDA Margin %. This puts Medline in the upper half of its industry. The industry median EBITDA Margin % is 7.48. Medline's value of 9.66% is 29.2% above this benchmark. Historically, Medline's own EBITDA Margin % has ranged from 8.46 to 12.10 over the past decade. While the company's 10-year median is 10.12 vs. the industry median of 7.48, Medline has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medline's current EBITDA Margin % of 9.66% is 29.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medline and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medline's current EBITDA Margin % is 9.66%, which is near median its own 10-year median of 10.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medline stock overvalued right now?
Medline (MDLN) has a current EBITDA Margin % of 9.66%. The current EBITDA Margin % is 9.66%, which is near median its 10-year median of 10.12 and 29.2% above the Medical Devices & Instruments industry median of 7.48. Medline's overall GF Score™ is 16/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Medline (MDLN), the current EBITDA Margin % is 9.66% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Medline is the largest provider of medical-surgical products and supply chain solutions in the US. The company generates over 90% of its revenue domestically and serves some of the largest US health systems. Medline offers approximately 190,000 Medline-branded products across more than 250 product families—including front-line care, surgical solutions, and laboratory and diagnostics—as well as roughly 150,000 third-party products sourced from over 1,250 vendors. The company maintains prime vendor relationships with many customers, acting as the primary consolidated logistics partner for their medical-surgical needs. Medline has significant scale, supported by more than 30 manufacturing facilities and a fleet of over 2,000 owned delivery trucks. Medline went public in December 2025.
16GF Score
Get the complete analysis for MDLN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDLN has been successfully added to your 
